Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting PR Newswire - Tue Apr 21, 9:32AM CDT

Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial

NUVL : 108.85 (+1.61%)
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 PR Newswire - Fri Apr 17, 3:01PM CDT

Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in...

NUVL : 108.85 (+1.61%)
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC PR Newswire - Tue Apr 7, 5:30AM CDT

New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial

NUVL : 108.85 (+1.61%)
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 PR Newswire - Tue Mar 17, 4:15PM CDT

CAMBRIDGE, Mass. , March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 108.85 (+1.61%)
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire - Thu Feb 26, 5:30AM CST

Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of September...

NUVL : 108.85 (+1.61%)
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PR Newswire - Thu Feb 5, 5:30AM CST

CAMBRIDGE, Mass. , Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

NUVL : 108.85 (+1.61%)
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones PR Newswire - Mon Jan 12, 5:30AM CST

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026

NUVL : 108.85 (+1.61%)
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Mon Dec 22, 2025

CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 108.85 (+1.61%)
Nuvalent Appoints Ron Squarer to Board of Directors PR Newswire - Wed Dec 10, 2025

CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 108.85 (+1.61%)
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire - Wed Nov 26, 2025

CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 108.85 (+1.61%)

Barchart Exclusives

This Dividend Stock Keeps Hitting It Out of the Park: Should You Buy? Barchart - Wed Apr 22, 6:30PM CDT
Citigroup's financial performance has been impressive over the last couple of years as its transformation under CEO Jane Fraser is bearing fruit. Is the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.